Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Combining Imfinzi and Avastin with TACE led to better treatment outcomes.
Patients who received atezolizumab (Tecentriq) plus bevacizumab (Avastin) had a 28% lower risk of cancer recurrence or death.
Results in cell and mouse studies may have implications for the development of a new class of anticancer drugs.
Older people, immunocompromised people and those with underlying health conditions can benefit most from additional shots.
Imjudo plus Imfinzi improved overall survival compared with standard targeted therapy for hepatocellular carcinoma.
The lab is named after the late Steve W. Miller, a widely respected employee of Johnson & Johnson Consumer.
Protecting the immunocompromised is not only a matter of health equity, it’s critical to ending the pandemic.
Three checkpoint inhibitors reduce the risk of death for patients with hard-to-treat liver and biliary tract cancers.
Post-exposure and pre-exposure prophylaxis could be a game-changer for immunocompromised people.
Powell had received treatment for multiple myeloma, which can lead to poorer response to COVID-19 vaccines.
In a small study, 80% of participants treated with Cabometyx and Opdivo underwent successful surgery.
The booster is recommended for organ transplant recipients, people receiving cancer treatment and people with advanced or untreated HIV.
Stivarga also improved survival in those with recurrent HCC after a liver transplant.
Targeting a protein called cyclin D1 may be beneficial in cancer treatment in the setting of obesity and Type 2 diabetes.
Tecentriq plus Avastin improved improved overall survival and patient experiences during treatment.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.